---

#IPCALAB Highlights

- Strong HCQS sales in Q1 FY21, though uncertainty increases for future demand

- Strong operating performance and guidance shifts focus beyond HCQS

- FY21 guidance for 18% plus sales growth and margin expansion of 150 bps plus

- Resolution of US FDA import alerts a key near term factor to watch

HCQS (Hydroxychloroquine sulphate) was seen as a drug of choice to combat Covid-19 till recently.